Sareum
Holdings plc
("Sareum" or the
"Company")
Patent Allowance
for Crystalline Forms of SDC-1801 in
China
Cambridge, UK,
16 September 2024 - Sareum Holdings plc (AIM:
SAR), a clinical-stage biotechnology company developing
next-generation kinase inhibitors for autoimmune disease and
cancer, is pleased to announce that it has received a Notice of
Allowance from the China National Intellectual
Property Administration. This notice pertains to a patent
application protecting certain crystalline forms of SDC-1801, a
dual TYK2/JAK1 kinase inhibitor being developed as a
potential new therapeutic for a wide range of autoimmune
diseases.
The Chinese patent, application number
2021800259993, will provide
significant protection on several crystalline forms of SDC-1801 and
in the methods of their preparation. The Company anticipates the
Chinese patent to be granted by the end of 2024, subject to the
fulfilment of certain formalities. This is the first patent
allowance protecting crystalline forms of SDC-1801 in any
territory. Patent applications in other key territories, including
the US, Europe, Japan are under review.
Dr John
Reader, Sareum's Chief Scientific Officer,
commented: "We welcome the additional allowance from the
Chinese Patent Office, building on the recent approval of patents
protecting the molecular structure of SDC-1801 in all major
territories. This patent, covering various crystal forms,
complements our existing molecular structure patents and extends
the lifecycle of our patent estate. Combined with the
encouraging data from the Phase 1a trial, this strengthened IP
position gives us greater confidence as we look to advance SDC-1801
through clinical development, aiming to address unmet medical needs
in various autoimmune diseases."
- Ends -
For further
information, please contact:
|
Sareum Holdings plc
John Reader,
Chief Scientific Officer
|
01223 497700
ir@sareum.co.uk
|
|
Strand Hanson Limited (Nominated
Adviser)
James Dance / James
Bellman
|
020 7409 3494
|
|
Hybridan LLP (Corporate
Broker)
Claire Noyce
|
020 3764 2341
|
|
ICR Consilium (Financial
PR)
Jessica Hodgson / Davide Salvi
/ Kumail
Waljee
|
0203 709 5700
|
About
Sareum
Sareum Holdings (AIM:SAR) is a
clinical-stage biotechnology company
developing next generation kinase inhibitors for autoimmune disease
and cancer.
The Company is focused on developing
next generation small molecules which modify the activity of the
JAK kinase family and have best-in-class potential. Its lead
candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1.
SDC-1801 is a potential treatment for a range of autoimmune
diseases and has entered Phase 1a/b clinical development with an
initial focus on psoriasis.
Sareum is also developing SDC-1802,
a TYK2/JAK1 inhibitor with a potential application for cancer
immunotherapy.
Sareum Holdings plc is based in
Cambridge, UK, and is listed on the AIM market of the London Stock
Exchange, trading under the ticker SAR. For further information,
please visit the Company's website at www.sareum.com
